
February 26, 2024
RegMed Investors (RMi) Closing Bell: bubblicious sentiment?
February 26, 2024
RegMed Investors’ (RMi) pre-open: is the sector chewing “bubble” gum?
February 23, 2024
RegMed Investors (RMi) Closing Bell: yesterday’s ups and downs were switching positions
February 23, 2024
RegMed Investors’ (RMi) pre-open: caution and watch-out for re-calibrations
February 22, 2024
RegMed Investors (RMi) Closing Bell: will the “elevation” trend stay a friend?
February 22, 2024
RegMed Investors’ (RMi) pre-open: Fragility risks are high, vulnerable liquidity with gliding volatility
February 21, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy equities closes barely positive
February 21, 2024
RegMed Investors (RMi) Research Note:CRISPR Therapeutics (CRSP) announces Registered Direct Offering (RDO) of $280 M priced at $71.50 per share
February 20, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy equities falter, led by Nasdaq
February 20, 2024
RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors